Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY: CYBN )

9.530 UNCHANGED
Streaming Delayed Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
32 33 34 35 36 37 38 39 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
Psychedelics company Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced that the U.S. Patent and Trademark Office  has granted U.S. patent 11,242,318 to the company’s investigational deuterated... 
Via Benzinga
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Cybin's Vision Strengthens Position In Emerging Wellness Trend
Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health... 
Via Benzinga
Cybin Schedules Release of Q3 Results, Conference Call
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62 
Via Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 9.82% at $1.23 
Via Benzinga
Cybin Marks 2021 Accomplishments, Eyes 'Transformative' 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Marks 2021 Accomplishments, Eyes ‘Transformative’ 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE. 
Via Benzinga
Psychedelic Stocks Finally In An Upswing
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week. 
Via Talk Markets
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19 
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17 
Via Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69 
Via Benzinga
Cybin's IRB-Approved Study Begins Enrollment This Year
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Upcoming study supports CYBN’s mission to develop psychedelics... 
Via Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Begins Enrollment This Year
Via Investor Brand Network
Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants
Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants. 
Via Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year
Via Investor Brand Network
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57 
Via Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Position in Emerging Wellness Trend
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Schedules Release of Q3 Results, Conference Call
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call
Via Investor Brand Network
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
32 33 34 35 36 37 38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.